Skip to Content

Ezogabine Pregnancy and Breastfeeding Warnings

Ezogabine is also known as: Potiga

Ezogabine Pregnancy Warnings

-Not recommended during pregnancy and in women of childbearing age not using contraception. (UK) -This drug should be used during pregnancy only if the benefit outweighs the risk to the fetus. (US) US FDA pregnancy category: C

Animal studies have revealed evidence of increased pre- and postnatal mortality, developmental toxicity, increased fetal skeletal variations, decreased fetal body weights, and delayed reflex development (e.g., auditory startle response development) in offspring. There was no effect on fertility or general reproductive performance, but the plasma levels achieved in these studies were less than those reached in humans at recommended doses. There are no controlled data in human pregnancy, and the effects on human labor and delivery are unknown. The risk of congenital malformations, such as cleft lip and neural tube defects, is increased by a factor of 2 to 3 in the offspring of mothers treated with antiepileptic drugs compared with the expected incidence in the general population of approximately 3%. Therapy with multiple antiepileptic drugs is associated with a higher risk of congenital malformations than monotherapy and therefore monotherapy should be used whenever possible. To monitor the outcomes of pregnant women exposed to this drug, physicians are advised to recommend pregnant patients enroll in the North American Antiepileptic Drug (NAAED) Pregnancy Registry by calling 1-888-233-2334; enrollment must be done by patients themselves. Information on the registry can be found at US FDA pregnancy category C: Animal reproduction studies have shown an adverse effect on the fetus and there are no adequate and well-controlled studies in humans, but potential benefits may warrant use of the drug in pregnant women despite potential risks.

See references

Ezogabine Breastfeeding Warnings

A decision should be made to discontinue breastfeeding or discontinue the drug, taking into account the importance of the drug to the mother. Excreted into human milk: Unknown Excreted into animal milk: Yes Comments: The effects in the nursing infant are unknown.

See references

References for pregnancy information

  1. "Product Information. Potiga (ezogabine)." GlaxoSmithKline, Research Triangle Park, NC.

References for breastfeeding information

  1. "Product Information. Potiga (ezogabine)." GlaxoSmithKline, Research Triangle Park, NC.

Disclaimer: Every effort has been made to ensure that the information provided by Cerner Multum, Wolters Kluwer Health and is accurate, up-to-date and complete, but no guarantee is made to that effect. In addition, the drug information contained herein may be time sensitive and should not be utilized as a reference resource beyond the date hereof. This material does not endorse drugs, diagnose patients, or recommend therapy. This drug information is a reference resource designed as supplement to, and not a substitute for, the expertise, skill , knowledge, and judgement of healthcare practitioners in patient care. The absence of a warning for a given drug or combination thereof in no way should be construed to indicate that the drug or combination is safe, effective, or appropriate for any given patient. Multum Information Services, Inc. does not assume any responsibility for any aspect of healthcare administered with the aid of information Multum provides. Copyright 2000-2008 Multum Information Services, Inc. The information contained herein is not intended to cover all possible uses, directions, precautions, warnings, drug interactions, allergic reactions, or adverse effects. If you have questions about the drugs you are taking, check with your doctor, nurse, or pharmacist.